BCM
TBIO

BlueCrest Capital Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

BlueCrest Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,186
Closed -$192K – 1601
2018
Q3 		$192K Buy
+19,186
New +$223K 0.01% 1284

Other funds holding TBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlueCrest Capital Management's TBIO Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q4 2018, closing a stake of 19,186 shares — an estimated $192K sold.

BlueCrest Capital Management first reported a position in TBIO in Q3 2018 and held it in 1 quarter. The position peaked at $192K in Q3 2018. 47 funds tracked by Wall St. Rank hold TBIO as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Translate Bio, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 19,186 Translate Bio, Inc. Common Stock shares in Q4 2018, an estimated $192K.
  • BlueCrest Capital Management first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Translate Bio, Inc. Common Stock position peaked at $192K in Q3 2018.
  • 47 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.